Compare GT & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | OGN |
|---|---|---|
| Founded | 1898 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2005 | 2020 |
| Metric | GT | OGN |
|---|---|---|
| Price | $6.29 | $6.20 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 4 |
| Target Price | $10.56 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 7.4M | 3.1M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | ★ $18,280,000,000.00 | $6,216,000,000.00 |
| Revenue This Year | N/A | $0.42 |
| Revenue Next Year | $3.38 | $1.67 |
| P/E Ratio | ★ N/A | $8.65 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.36 | $6.16 |
| 52 Week High | $12.03 | $15.85 |
| Indicator | GT | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 19.60 | 28.91 |
| Support Level | N/A | $6.18 |
| Resistance Level | $8.75 | $7.87 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 2.00 | 3.69 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.